Premium
Preemptive treatment of early donor‐specific antibodies with IgA‐ and IgM‐enriched intravenous human immunoglobulins in lung transplantation
Author(s) -
Ius Fabio,
Verboom Murielle,
Sommer Wiebke,
Poyanmehr Reza,
Knoefel AnnKathrin,
Salman Jawad,
Kuehn Christian,
Avsar Murat,
Siemeni Thierry,
Erdfelder Caroline,
Hallensleben Michael,
Boethig Dietmar,
Schwerk Nicolaus,
Mueller Carsten,
Welte Tobias,
Falk Christine,
Haverich Axel,
Tudorache Igor,
Warnecke Gregor
Publication year - 2018
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14912
Subject(s) - medicine , antibody , plasmapheresis , lung transplantation , transplantation , gastroenterology , donor specific antibodies , retrospective cohort study , immunology , kidney transplantation
This retrospective study presents our 4‐year experience of preemptive treatment of early anti‐ HLA donor specific antibodies with IgA‐ and IgM‐enriched immunoglobulins. We compared outcomes between patients with antibodies and treatment (case patients) and patients without antibodies (control patients). Records of patients transplanted at our institution between March 2013 and November 2017 were reviewed. The treatment protocol included one single 2 g/kg immunoglobulin infusion followed by successive 0.5 g/kg infusions for a maximum of 6 months, usually combined with a single dose of anti‐ CD 20 antibody and, in case of clinical rejection or positive crossmatch, with plasmapheresis or immunoabsorption. Among the 598 transplanted patients, 128 (21%) patients formed the case group and 452 (76%) the control group. In 116 (91%) patients who completed treatment, 106 (91%) showed no antibodies at treatment end. Fourteen (13%) patients showed antibody recurrence thereafter. In case versus control patients and at 4‐year follow‐up, respectively, graft survival (%) was 79 versus 81 ( P = .59), freedom (%) from biopsy‐confirmed rejection 57 versus 53 ( P = .34), and from chronic lung allograft dysfunction 82 versus 78 ( P = .83). After lung transplantation, patients with early donor‐specific antibodies and treated with IgA‐ and IgM‐enriched immunoglobulins had 4‐year graft survival similar to patients without antibodies and showed high antibody clearance.